Mode
Text Size
Log in / Sign up

CBT-based psychoeducation improves anger control and death anxiety in cancer patients receiving chemotherapyEight CBT sessions help cancer patients control anger and fear of death

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider CBT-based psychoeducation for anger and death anxiety in cancer patients receiving chemotherapy.

This randomized controlled trial involved 80 individuals receiving chemotherapy, divided into 40 for the control group and 40 for the experimental group. The intervention consisted of eight sessions of CBT-based psychoeducation, while the comparator was a standard control group. The setting and publication type were not reported in the available data.

The primary outcomes assessed were anger control and death anxiety. Results indicated that the gap between pretest and posttest scores was statistically significant for both measures, with p-values less than .05. The direction of change was improvement for both the anger scale total scores and the death anxiety scale total scores.

No absolute numbers or effect sizes were reported for the outcomes. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. The follow-up period was also not reported. Funding or conflicts of interest were not reported.

The practice relevance suggests that CBT-based psychoeducation can be recommended as a professional psycho-oncology practice to improve anger and anxiety in individuals with cancer. However, the lack of reported effect sizes and safety data limits the ability to fully assess the intervention's clinical utility.

People with cancer often face intense emotions. Anger and fear of death can make the treatment journey harder. A new trial looked at whether a specific type of counseling could help. Eighty individuals receiving chemotherapy were split into two groups. One group received eight sessions of CBT-based psychoeducation. The other group served as a control. This approach uses cognitive behavioral therapy principles to teach coping skills. The results showed clear benefits for those who received the counseling. Their anger scores improved significantly from before the program to after. Their fear of death also decreased in a statistically significant way. Both changes were positive and meaningful for the participants. No safety issues or side effects were reported during the study. The researchers suggest this method can be part of standard care. It offers a practical way to support mental health alongside medical treatment. This approach fits well into professional psycho-oncology practices today.

What this means for you:
Eight CBT sessions improved anger control and reduced death anxiety in chemotherapy patients.

Study Details

Study typeRct
EvidenceLevel 2
PublishedMay 2026
View Original Abstract ↓
This study was conducted to examine the effect of Cognitive Behavioral Therapy (CBT)-based psychoeducation on anger control and death anxiety in individuals receiving chemotherapy. The research was completed as a pretest-posttest experimental design with 80 individuals who received chemotherapy (40 control, 40 experimental). The data were collected using the Personal Information Form, the Controlled Anger Scale (CAR), and the Death Anxiety Scale (DAS). Individuals in the experimental group received eight sessions of CBT-based psychoeducation. We used percent distribution, chi-square test, and test for dependent and independent groups were used to analyze the data. This study demonstrated that the gap among between the pretest and posttest total scores of the anger scale and death anxiety scale of the individuals in the CBT-based psychoeducation experimental group receiving chemotherapy was statistically significant ( < .05). CBT-based psychoeducation can be recommended as a professional psycho-oncology practice to improve the anger and anxiety in individuals with cancer.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.